Atricure Executives Make Significant Stock Sales
Atricure executives, including Director Sven Wehrwein and Chief Marketing Officer Justin J Noznesky, sold significant shares totaling over $569,000. Despite these sales, Atricure reported a strong Q3 with a 16% revenue increase to $134 million, improved profitability, and raised full-year revenue guidance to $532-534 million. The company is supported by successful product launches and international sales growth. Spark rates ATRC stock as 'Outperform' due to strong financial performance, though valuation concerns exist.
New insider activity at Atricure ( (ATRC) ) has taken place on November 26, 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
In recent transactions involving Atricure stock, Director Sven Wehrwein sold 10,000 shares, amounting to a total of $376,577. Additionally, Chief Marketing and Strategy Officer Justin J Noznesky sold 5,166 shares, with the sale valued at $192,640.
Recent Updates on ATRC stock
AtriCure, Inc. recently reported a strong Q3 performance with a 16% year-over-year revenue increase to $134 million, driven by successful product launches and international sales growth. The company improved its profitability, achieving nearly $18 million in adjusted EBITDA and generating over $30 million in cash. Key growth drivers included the AtriClip platform, cryoSPHERE devices, and EnCompass clamp, with significant expansion in appendage management and pain management segments. Despite challenges in the minimally invasive ablation and hybrid therapy markets, AtriCure raised its full-year revenue guidance to $532-534 million, reflecting a positive outlook supported by a solid cash position and strategic investments in innovation and clinical science.
Spark’s Take on ATRC Stock
According to Spark, TipRanks’ AI Analyst, ATRC is a Outperform.
Atricure’s overall stock score is driven by strong financial performance and positive technical indicators. The earnings call highlighted significant growth and raised guidance, contributing to a high score. However, valuation concerns due to negative profitability metrics slightly offset these strengths.
To see Spark’s full report on ATRC stock, click here.
More about Atricure
YTD Price Performance: 26.58%
Average Trading Volume: 476,965
Technical Sentiment Signal: Buy
Current Market Cap: $1.91B
